<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836483</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-15-2-01</org_study_id>
    <nct_id>NCT02836483</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</brief_title>
  <official_title>A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II
      Trial of LCB01-0371.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to explore antituberculosis of LCB01-0371 through the assess of the
      early bactericidal activity, safety of administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2016</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EBA0-14</measure>
    <time_frame>V2(Baseline, Day 1), V9(Day 15)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from baseline at Day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EBA0-2</measure>
    <time_frame>V2(Baseline, Day 1), V4(Day 3)</time_frame>
    <description>The standard early bactericidal activity (standard EBA) expressed as the change of log colony forming units of sputum from baseline at Day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBA2-14</measure>
    <time_frame>V4(Day 3), V9(Day 15)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 3 at Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBA2-7</measure>
    <time_frame>V4(Day 3), V6(Day 8)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 2 at Day 8</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 400mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tubes 3~5Tablet, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyvox 600mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 1200mg, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 400mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tubes 3~5Tablet, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Tubes Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyvox 600mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Zyvox Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 1200mg, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Korean who After listening to understand the details about the clinical trial, decided
             to join in the clinical study, and written consent

          2. The age of consent at the time of writing, only men and women under 75 years old over
             19 years old

          3. The First diagnosis of tuberculosis and have not received tuberculosis treatment for
             TB patients

        Exclusion Criteria:

          1. Known history of Rifampicin or Isoniazid resistance

          2. Serious TB for example tuberculous encephalomeningitis, It is impossible to
             participate in clinical trials

          3. Known History of nontuberculous mycobacteria positive

          4. Other pulmonary disease which is impossible to participate in clinical trial except TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.S Sim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Delpazolid</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

